Published in Oncotarget on February 28, 2015
A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection. PLoS One (2015) 0.81
Overexpression of RACK1 Promotes Metastasis by Enhancing Epithelial-Mesenchymal Transition and Predicts Poor Prognosis in Human Glioma. Int J Environ Res Public Health (2016) 0.77
Development of a prognosis-prediction model incorporating genetic polymorphism with pathologic stage in stage I non-small cell lung cancer: A multicenter study. Thorac Cancer (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Replicating genotype-phenotype associations. Nature (2007) 16.11
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature (1996) 10.81
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 8.72
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
The new lung cancer staging system. Chest (2009) 6.30
p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol (1999) 4.88
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Structures of complement component C3 provide insights into the function and evolution of immunity. Nature (2005) 4.01
Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. Proc Natl Acad Sci U S A (1994) 3.95
Assembly of centrosomal proteins and microtubule organization depends on PCM-1. J Cell Biol (2002) 3.86
Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell (2004) 3.73
Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer (2004) 3.64
RACK1, A multifaceted scaffolding protein: Structure and function. Cell Commun Signal (2011) 2.16
The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem (1999) 1.77
Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet (2004) 1.70
CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res (1997) 1.70
RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site. Mol Biol Cell (2003) 1.65
Cancer and the complement cascade. Mol Cancer Res (2010) 1.64
PCM-1, A 228-kD centrosome autoantigen with a distinct cell cycle distribution. J Cell Biol (1994) 1.43
Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene (2004) 1.33
RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J (2000) 1.30
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer (2005) 1.27
The WD protein Rack1 mediates protein kinase C and integrin-dependent cell migration. J Cell Sci (2001) 1.27
The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle (2012) 1.24
Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz) (2011) 1.15
Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer (2009) 1.09
RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Oncogene (2006) 1.09
Arrest of cell cycle progression during first interphase in murine zygotes microinjected with anti-PCM-1 antibodies. Cell Motil Cytoskeleton (2002) 1.05
RACK1: A superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer (2010) 1.05
The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann N Y Acad Sci (1976) 0.98
RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat (2010) 0.95
RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J Cancer (2008) 0.90
Immunoglobulins and complement components levels in patients with lung cancer. Rom J Intern Med (1992) 0.89
PCAF is a coactivator for p73-mediated transactivation. Oncogene (2003) 0.87
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol (2013) 0.86
Associations of genetic variants in the transcriptional coactivators EP300 and PCAF with hepatocellular carcinoma. Cancer Epidemiol (2012) 0.82
The p300/CBP associated factor is frequently downregulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome. Cancer Biol Ther (2009) 0.80
A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females. J Thorac Oncol (2014) 0.79
A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection. PLoS One (2015) 0.81
Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery. Oncotarget (2015) 0.78
A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. Oncotarget (2016) 0.77
Polymorphisms in Epithelial-Mesenchymal Transition-Related Genes and the Prognosis of Surgically Treated Non-small Cell Lung Cancer. Ann Surg Oncol (2017) 0.75